Hoosier Cancer Research Network is happy to celebrate the research accomplishments of our members over the past year. Congratulations to all researchers and study teams whose hard work produced 23 journal manuscripts and meeting abstracts between July 1, 2023, and June 30, 2024!

Journal Manuscripts

 HCRN-GI14-198: Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients

• Journal: European Journal of Cancer (August 2023)
• Link: https://www.ejcancer.com/article/S0959-8049(23)00128-4/abstract
• Authors: Walid L. Shaib, Rupji Manali, Yuan Liu, Bassel El-Rayes, Patrick Loehrer, Bert O’Neil, Steven Cohen, Tina Khair, Erwin Robin, Timothy Huyck, Tanios Bekaii-Saab

HCRN-GU15-262: Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

• Journal: JCO Precision Oncology (July 2023)
• Link: https://ascopubs.org/doi/abs/10.1200/PO.23.00095
• Authors: Deborah Doroshow, Peter O’Donnell, Jean Hoffman-Censits, Sumati V. Gupta, Ulka Vaishampayan, Elisabeth Heath, Philip Garcia, Qianqian Zhao, Menggang Yu, Matthew Milowsky, Matthew Galsky

HCRN-GU16-257: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial  

• Journal: Nature Medicine (October 2023)
• Link: https://www.nature.com/articles/s41591-023-02568-1
• Authors: Matthew Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin Chan, Sara Lewis, Bassam El Achkar, Tanya Dorff, Jeremy Paul Cetnar, Brock Neil, Anishka D’Souza, Ronac Mamtani, Christos Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horwitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, G. Kenneth Haines, Li Wang, Kent Mouw, Robert Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John Sfakianos, Sumanta K. Pal

HCRN-GU17-294: Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade

• Journal: American Cancer Society Journals (January 2024)
• Link: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35179
• Authors: Eric Miller, Tracy Rose, Benjamin Maughan, Matthew Milowsky, Mehmet Bilen, Bradley Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang Yu, Neeraj Agarwal, Matthew Galsky

HCRN-LUN13-175: Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer

• Journal: The Oncologist (January 2024)
• Link: https://academic.oup.com/oncolo/article/29/1/47/7216374
• Authors: Ryan Gentzler, Nisha Mohindra, Shadia Jalal, Karen Reckamp, Richard Hall, Nasser Hanna, Young Kwang Chae, Marianna Koczywas, Irene Helenowski, Jyoti Patel

HCRN-LUN15-299: Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma

• Journal: The Journal of Thoracic Oncology (December 2023)
• Link: https://www.jtocrr.org/article/S2666-3643(23)00127-3/fulltext
• Authors: Arkadiusz Dudek, Min Xi, Katherine Scilla, Hirva Mamdani, Benjamin Creelan, Andreas Saltos, Tawee Tanvetyanon, and Alberto Chiappori.

MMP-MEL18-372: The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma

• Journal: Melanoma Research (December 2023)
• Link:https://journals.lww.com/melanomaresearch/abstract/2023/12000/the_combination_of_pac_1_and_entrectinib_for_the.9.aspx
• Authors: Matthew Boudreau, Emily Tonogai, Claire Schane, Min X. Xi, James Fischer, Jayanthic Vijayakumar, Yanc Ji, Theodore Tarasow, Timothy Fan, Paul Hergenrother, Arkadiusz Dudek

HCRN Manuscript: The Endpoints Dataset: A Quality Control Method for Review and Analysis of Critical Efficacy Endpoints Data

• Journal: Journal of the Society for Clinical Data Management (Spring 2024)
• Link: https://www.jscdm.org/article/id/174/
• Authors: Timothy Breen, Adelai Neal

Meeting Abstracts

HCRN-BRE18-360: TIPS-21 Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA)

• Meeting: 2023 SNO/ASCO CNS Cancer Conference (August 2023)
• Abstract Type: Trials in Progress
• Link: https://academic.oup.com/noa/article/5/Supplement_3/iii39/7237072
• Authors: Colette Shen, Yara Abdou, Linda Chen, Xianming Tan, Gaorav Gupta, Filipa Lynce, Mina Lobbous, Erica Stringer-Reasor, Carey Anders

HCRN-BRE18-360: Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA)

• Meeting: SABCS (December 2023)
• Abstract Type: Poster (PO5-20-03)
• Authors: Colette Shen, Yara Abdou, Linda Chen, Xianming Tan, Gaorav Gupta, Filipa Lynce, Mina Lobbous, Erica Stringer-Reasor, Carey Anders

HCRN-BRE21-516: TIPS-19 Trial in Progress: Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET)

• Meeting: 2023 SNO/ASCO CNS Cancer Conference (August 2023)
• Abstract Type: Trials in Progress
• Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402322/
• Authors: Sarah Sammons, Amanda E. D. Van Swearingen, Laura Noteware, Nusayba A. Bagegni, Kelly Moulton, Stevie Threatt, Denise Jaggers, Shannon Shea, Eric S. Lipp, Erin Riley, Sin-Ho Jung, Gloria Broadwater, Masey Ross, Kimberly Strickland, Sasha Beyer, Alison Conlin, Aki Morikawa, Rashmi Murthy, Carey K. Anders

HCRN-BRE21-516: Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET)

• Meeting: SABCS (December 2023)
• Abstract Type: Poster (PO5-20-02)
• Authors: Sarah Sammons, Amanda E. D. Van Swearingen, Laura Noteware, Nusayba A. Bagegni, Kelly Moulton, Stevie Threatt, Denise Jaggers, Shannon Shea, Eric S. Lipp, Erin Riley, Sin-Ho Jung, Gloria Broadwater, Masey Ross, Kimberly Strickland, Sasha Beyer, Alison Conlin, Aki Morikawa, Rashmi Murthy, Carey K. Anders

HCRN-GU16-260: 1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell

• Meeting: SITC (November 2023)
• Abstract Type: Poster Presentation:
• Link: https://jitc.bmj.com/content/11/Suppl_1/A1125
• Authors: Miya Hugaboom, Kelly Street, Neil Ruthen, Lena Wirth, Opeyemi A Jegede, Nicholas Schindler, David F McDermott, Elizabeth Plimack, Jeffrey Sosman, Naomi B Haas, Michael Hurwitz, Hans Hammers, Sabina Signoretti, Michael B Atkins, Catherine J Wu, David Braun

HCRN-GU16-260: Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC)

• Meeting: ASCO GU (January 2024)
• Abstract Type: Poster
• Link: https://meetings.asco.org/abstracts-presentations/229933
• Authors: Nourhan El Ahmar, Sayed Matar, Opeyemi Jegede, Yasmin Nabil Laimon, Varunika Savla, Aseman Bagheri Sheshdeh, Thomas Denize, Razan Assaad Mohanna, Toni K. Choueiri, Paul J. Catalano, David A. Braun, Naomi B. Haas, Hans J. Hammers, Mehmet Asim Bilen, Mark N. Stein, Jeffrey A. Sosman, Catherine J. Wu, David F. McDermott, Michael B. Atkins, Sabina Signoretti

HCRN-GU16-260: Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC)

• Meeting: ASCO (May 2024)
• Abstract Type: Poster
• Link: https://meetings.asco.org/abstracts-presentations/231926
• Authors: Jacob Zaemes, Miya Hugaboom, Valisha Shah, Naomi Haas, David McDermott, Opeyemi Jegede, Mehmet Bilen, Mark Stein, Jeffrey Sosman, Robert Alter, Elizabeth Plimack, Michael Hurwitz, Catherine Wu, David Einstein, Hans Hammers, Sabina Signoretti, Destiny West, Thomas Denize, Michael Atkins, David Braun

HCRN-GU20-436: A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

• Meeting: ASCO GU (January 2024)
• Abstract Type: Trials in Progress
• Link: https://meetings.asco.org/abstracts-presentations/230427
• Authors: Rana R. McKay, Lin Liu, Minya Pu, Arlene Araneta, Luke Wang, Neremiah Castano, Jennifer Gomez, Archana Ajmera, Huihui Ye, Roberto Pili, Karie Runcie, Deaglan Joseph McHugh, Kenneth Offit, Channing Judith Paller, Naomi B. Haas, Juan Javier-Desloges, Christopher J. Kane, Tyler M Seibert, Aditya Bagrodia

HCRN-GU20-436: A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

• Meeting: ASCO (June 2024)
• Abstract Type: Poster
• Link: https://meetings.asco.org/abstracts-presentations/238462
• Authors: Rana R. McKay, Lin Liu, Minya Pu, Arlene Araneta, Luke Wang, Neremiah Castano, Jennifer Gomez, Archana Ajmera, Huihui Ye, Roberto Pili, Karie Runcie, Deaglan Joseph McHugh, Kenneth Offit, Channing Judith Paller, Naomi B. Haas, Juan Javier-Desloges, Christopher J. Kane, Tyler M Seibert, Aditya Bagrodia

HCRN-GU21-517: A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)

• Meeting: ASCO GU (January 2024)
• Abstract Type: Trials in Progress
• Link: https://meetings.asco.org/abstracts-presentations/230420
• Authors: Yu-Wei Chen, Lin Liu, Minya Pu, Samuel Pena, Qian Qin, Tian Zhang, Hamid Emamekhoo, Joshua Michael Lang, Akash Patnaik, Rana R. McKay

HCRN-GU22-587: Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT).

• Meeting: ASCO GU (January 2024)
• Abstract Type: Trials in Progress
• Link: https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.4_suppl.TPS492
• Authors: Michael Serzan, Opeyemi Jegede, Robert Alter, Mehmet Asim Bilen, David Braun, David Einstein, Naomi Haas, Hans Hammers, David Herchenhorn, Jennifer King, Karie Runcie, Jeffrey Sosman, Cora Sternberg, Yuanquan Yang, Toni Choueiri, Sabina Signoretti, Michael B. Atkins

HCRN-GU22-587: Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT).

• Meeting: ASCO (June 2024)
• Abstract Type: Poster
• Link: https://meetings.asco.org/abstracts-presentations/238451
• Authors: Michael Serzan, Opeyemi Jegede, Robert Alter, Mehmet Asim Bilen, David Braun, David Einstein, Naomi Haas, Hans Hammers, David Herchenhorn, Jennifer King, Karie Runcie, Jeffrey Sosman, Cora Sternberg, Yuanquan Yang, Toni Choueiri, Sabina Signoretti, Michael B. Atkins

HCRN-LUN18-335: LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

• Meeting: ESMO Congress (October 2023)
• Abstract Type: Mini Oral Session
• Link: https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/a-multi-centre-open-label-randomized-phase-ii-study-of-osimertinib-with-and-without-ramucirumab-in-tki-naive-egfr-mutant-metastatic-nsclc-ramose-t
• Authors: Xiuning Le, Jyoti Patel, Elaine Shum, Joshua Sabari, Christina Baik, Rachel Sanborn, Katherine Shu, Chul Kim, Mary Jo Fidler, Richard Hall, Nasser Hanna, Jhanelle Gray, John V. Heymach, Andreas Saltos

HCRN-LUN21-530: A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART

• Meeting: ASCO (June 2024)
• Abstract Type: Poster
• Link: https://meetings.asco.org/abstracts-presentations/238527
• Authors: Hirva Mamdani, Seongho Kim, Ryan D. Gentzler, Misty Dawn Shields, Muhammad Furqan, Kristen Pizana, Qura Abid, Shadia Ibrahim

HCRN-MEL17-309: Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma  

• Meeting: ASCO (June 2024)
• Abstract Type: Rapid Oral Abstract
• Link: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.9509
• Authors: Suthee Rapisuwon, Richard D. Carvajal, George Ansstas, Katy K. Tsai, Leonel Fernando Hernandez-Aya, Shaheer Khan, Sunandana Chandra, J. William Harbour, Jeffrey A. Sosman, Adil Daud, Christina Decatur, Deniz Ozisik, Ming Tony Tan, Michael B. Atkins, Sapna Pradyuman Patel 

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants in have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.